Question: SK Hynix debuts on Nasdaq as SKHY (~Jul 10). What does a record $29.4B ADR mean for an already-huge public company, what does its Seoul tape look like (and why is it "wonky"), and why is the HBM monopoly US-listing at all?

Verdict: Watch — the memory-supercycle monopolist monetizing at a record valuation. A clean USD-denominated way to own HBM #1, but SKHY debuts into a parabolic, −21.6%-off-high, 10–15%-daily-swing tape and stacks $29B of new supply. Structural confirmation of the memory-supercycle thesis; not a "buy the debut" signal.

What we're asking

Zoom's move was a windfall dressed up as a business. SK Hynix is the opposite question: a company that makes absurd operating money is choosing to list a second time, in dollars, on Nasdaq. They're debuting as SKHY this week — what does that mean for the ADR, why is the Seoul tape wonky, and why list in the US at all when you're already a mega-cap?

What we found

1. The listing (verified): SKHY, ~Jul 10, a record-scale raise

• Ticker SKHY, Nasdaq, trading expected to start ~July 10, 2026 (CNBC, BigGo, WEEX).
• ~$29.4B raise, 17.79M new ADS (registered on an SEC F-1) — the largest-ever ADR listing, past Alibaba's 2014 debut; at the top end among the largest share sales in history. Underwriters BofA / Citi / Goldman / JPMorgan. Proceeds → advanced memory fabs in Korea + chipmaking equipment, explicitly ASML EUV scanners (per the June 24 filing news; Quartz).
• ADR ratio: 10 ADRs = 1 common share. With the Seoul share ₩2.34M, one ADR ≈ ₩234K ≈ **$155–160** at spot FX — a normal, buyable US price built off a ₩2.3M Korean share.

2. What this means for "the ADR" — sponsored + listed is a different animal

The key distinction: like most big Korean names, SK Hynix has been reachable in the US only through thin, unsponsored OTC ADRs (and a German proxy, HY9H.F) — no capital raised, no real liquidity, no index eligibility. SKHY is its first sponsored, exchange-listed, capital-raising ADR. That changes three things:

1. It's primary, not just access: 17.79M new shares — the company raises ~$29B (dilutive), it isn't only wrapping existing stock. The unsponsored OTC line was pure access; SKHY is a fundraise.
2. Real liquidity + eligibility: a listed Nasdaq line opens US index/passive inclusion paths and lets US funds that can't touch KRX hold it directly.
3. Two venues, one company, arbitrage-linked: SKHY and 000660.KS are the same equity in different currencies/time-zones; the ADR will track Seoul (± FX and the ~15-hour session gap). A US holder is taking KRW/USD and Korea-session risk, not escaping it.

3. The Seoul tape (000660.KS) — parabolic, and genuinely wonky

The Seoul parabola, annotated (live 000660.KS closes; the table below has the full detail):

Raw closes (KRW):

Why it looks wonky:

• ~11x in a year (₩270K → ₩2.99M high) — a near-vertical parabola, ~+300%+ YTD in Seoul; it passed Samsung as Korea's most valuable company mid-run.
• Brutal swings for a mega-cap — 10–15% single days (the −9.9% KOSPI crash; the Jul-2 air-pocket). A trillion-won company should not move like a small-cap; the HBM cycle + index concentration makes it do so.
• High nominal price — ₩2.3M/share (~$1,600) because Korean names rarely split; that alone makes the chart look strange to US eyes. The 10:1 ADR ratio is partly a fix for exactly this.
• Now −21.6% off the high but still up enormously — a violent pullback inside a monster uptrend, not a top called.

4. Why list in the US at all — it's not "more volume," it's four structural levers

1. Capital depth. $29.4B is a lot — the largest ADR ever. Even Korea's biggest company can't repeatedly pull raises of that size from the domestic pool without moving its own stock; US markets are the only venue deep enough to absorb it cleanly.
2. Dollar funding for dollar capex — a natural hedge. Proceeds buy ASML EUV tools and fab equipment priced in USD/EUR. Raising USD to spend USD removes the FX mismatch of raising KRW and converting.
3. Escape the "Korea discount." Korean equities chronically trade at a governance/chaebol discount; US-listed AI-semis trade at richer multiples. A Nasdaq line is a bid for a valuation re-rate toward the US comp set (this is the memory-supercycle "Memorable 3 > Mag7" tension made literal).
4. Investor base + passive flows + prestige. Direct access for US institutions that won't/can't hold KRX, a path to US index inclusion, and a marquee listing that plants the HBM monopoly squarely in the US AI trade. Volume/liquidity is a consequence of these, not the reason.

5. The money — this is monopoly-rent economics

Q1 2026 (company release, all-time records): revenue ₩52.58T (~$35.5B), +198% YoY / +60% QoQ; operating profit ₩37.61T at a ~72% operating margin; net ~₩40.3T at ~77% net margin (SK hynix IR, CNBC). HBM #1 at 56.4% share; HBM4E samples H2 2026, mass production 2027. A 72% operating margin on a hardware business is the whole thesis in one number — that is HBM scarcity rent, not normal semiconductor economics. "They make SO much money" is, if anything, an understatement.

Verdict + reasoning

The SKHY listing is a structural datapoint, not a trade. The single most important memory company on earth is choosing to monetize the cycle at a record dollar valuation, buy more ASML EUV, and re-rate toward US semis. That is the memory-supercycle thesis confirming itself in the primary market — the monopolist is behaving exactly as "AI capex → HBM cannibalizes DRAM → all-memory tightness" predicts, and it's putting a $29B exclamation point on it.

For the desk's tradeable reads (per the lane):

• MU is the US-listed comp and the cleaner instrument for the same thesis — diversified, dollar-native, no KRW/Korea-session overhang, already a focus name. SKHY's records and re-rate are a tailwind read-through to MU.
• ASML is levered directly: SK Hynix names EUV as a use of proceeds — a $29B war chest earmarked partly for ASML tools.
• DRAM / RAM (Roundhill Memory ETFs) are the basket vehicles; treat any "ETF bid on the news" as web-reported until the tape confirms it.

For the curious-but-not-owning question (you): SKHY is the cleanest pure way to own the HBM monopoly in USD — but you'd be buying it (a) into a parabola that's already −21.6% off its high with 10–15% daily swings, and (b) as it prints $29B of brand-new supply the market has to absorb in its first days (IPO-allocation selling + no trading history = a wide, jumpy debut). The business is extraordinary; the entry is a mega-cap IPO on top of a vertical move — the two are not the same decision. Cleaner exposure to the identical thesis already exists in MU. Per the desk's own book (trend-hold, not chase-the-parabola), SKHY is a watch-the-debut, not a buy-the-open.

Watch triggers:

• SKHY debut tape (Jul 10 →): allocation-selling air-pocket vs. index-inclusion bid; a clean base after the debut is the entry, not the open. Buying the first print of a record ADR is buying maximum momentum.
• KRW/USD: the ADR carries currency; a weak-won move can eat a right thesis (and vice-versa).
• HBM4E timeline (samples H2 2026 → mass production 2027): slippage is the first crack in the monopoly-rent story; on-schedule hardens it.
• Memory-cohort tape (MU / the memory-supercycle set): SKHY records that don't lift MU would signal the re-rate is Korea-idiosyncratic, not a sector read.
• #1 lane risk unchanged — capex glut: a record raise funding record fab build-out is the supercycle's own seeds-of-reversal; ₩72% margins invite everyone's capex.

Sources: CNBC, BigGo, WEEX, Quartz, SK hynix IR. Fundamentals are company-reported — SK Hynix is a foreign filer with no US filings yet (pre-listing), so these ₩ figures are single-source.